{
  "id": 1767462598884,
  "title": "Optic Neuropathy: Clinical Assessment & Neuro-Ophthalmology Guide",
  "summary": "A comprehensive clinical framework for assessing optic nerve injuries from local and systemic diseases. This guide covers typical and atypical optic neuritis, Multiple Sclerosis (MS), and Neuromyelitis Optica Spectrum Disorders (NMOSD).",
  "date": "2026-01-03T17:49:58.884Z",
  "data": {
    "title": "Optic Neuropathy: Clinical Assessment & Neuro-Ophthalmology Guide",
    "summary": "A comprehensive clinical framework for assessing optic nerve injuries from local and systemic diseases. This guide covers typical and atypical optic neuritis, Multiple Sclerosis (MS), and Neuromyelitis Optica Spectrum Disorders (NMOSD).",
    "summary_illustration": "<svg viewBox='0 0 200 200' xmlns='http://www.w3.org/2000/svg'><circle cx='100' cy='100' r='80' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='4'/><circle cx='100' cy='100' r='30' fill='hsl(215, 90%, 45%)' opacity='0.3'/><path d='M100 20 L100 180 M20 100 L180 100' stroke='hsl(215, 90%, 45%)' stroke-width='2' stroke-dasharray='4'/><path d='M60 100 Q100 40 140 100 Q100 160 60 100' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='3'/><circle cx='100' cy='100' r='10' fill='hsl(215, 90%, 45%)'/><path d='M130 130 L170 170' stroke='hsl(215, 90%, 45%)' stroke-width='5' stroke-linecap='round'/></svg>",
    "sections": [
      {
        "title": "Core Clinical Features",
        "icon": "visibility",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "The optic nerve is vulnerable to injury from numerous local and systemic diseases.",
          "Clinical features include: dVA (decreased visual acuity).",
          "Relative/complete afferent pupillary defect.",
          "dlight sensitivity (decreased light sensitivity).",
          "dcolour vision (decreased colour vision).",
          "VF (Visual Field) defects.",
          "Optic disc abnormalities: swelling (early) and pallor (late) (see Table 16.1)."
        ]
      },
      {
        "title": "Table 16.1: An Approach to Assessing Optic Nerve Disease (History)",
        "icon": "history",
        "type": "table",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Category",
            "Details to Assess"
          ],
          "rows": [
            [
              "PC (Presenting Complaint)",
              "Blurring, ‘washout’ of colours, ‘blind spots’; may be asymptomatic; check duration, speed of onset/ recovery, precipitants, associations (diplopia, proptosis, red eye)"
            ],
            [
              "HPC (History of Presenting Complaint)",
              "Recent trauma or surgery"
            ],
            [
              "POH (Past Ocular History)",
              "Previous/ current eye disease; refractive error"
            ],
            [
              "PMH (Past Medical History)",
              "Vascular risk factors and disease; neurological disease (e.g. MS); connective tissue disease (e.g. SLE, RA); granulomatous disease (e.g. sarcoidosis, TB)"
            ],
            [
              "SR (Systems Review)",
              "Detailed review of all systems, particularly any headache or abnormalities of sensation/ motor system/ speech/ balance/ hearing and other systems, including respiratory, GI, GU, ENT systems"
            ],
            [
              "SH (Social History)",
              "Driver; profession; diet, tobacco consumption, alcohol intake, toxin exposure (e.g. lead, tin, or carbon monoxide)"
            ],
            [
              "FH (Family History)",
              "Family members with visual problems"
            ],
            [
              "Dx (Drug History)",
              "Previous/ current toxic drugs (e.g. anti- TB)"
            ],
            [
              "Ax (Allergies)",
              "Allergies or relevant drug contraindications"
            ]
          ]
        }
      },
      {
        "title": "Table 16.1: Assessment (Clinical Examination)",
        "icon": "clinical_notes",
        "type": "table",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Exam Element",
            "Findings to Check"
          ],
          "rows": [
            [
              "VA",
              "Best corrected/ pinhole/ near"
            ],
            [
              "Retinoscopy",
              "Rule out refractive error"
            ],
            [
              "Visual function",
              "Check for RAPD, colour vision, red desaturation, VF (confrontation VF and formal perimetry)"
            ],
            [
              "Orbit",
              "Proptosis, palpable mass, globe displacement, pulsation/ bruit"
            ],
            [
              "AS (Anterior Segment)",
              "Features suggestive of glaucoma, uveitis, carotid– cavernous fistula"
            ],
            [
              "Tonometry",
              "IOP"
            ],
            [
              "Optic disc",
              "Size, cup, colour, oedema, congenital abnormalities, flat/ elevated/ tilted, crowding, peripapillary oedema or haemorrhages, retinociliary collateral vessels, SVP"
            ],
            [
              "Macula",
              "Abnormalities which may cause central scotoma"
            ],
            [
              "Fundus",
              "Abnormalities (e.g. retinoschisis) that may cause peripheral field loss; posterior uveitis or vasculitis"
            ],
            [
              "Vessels",
              "Arteriosclerosis, hypertensive changes, occlusions, and emboli"
            ],
            [
              "CNS/ PNS",
              "Cranial nerves (including ocular motility); sensory, motor, cerebellar function; speech, mental state"
            ],
            [
              "CVS",
              "Pulse, heart sounds, carotid bruits"
            ]
          ]
        }
      },
      {
        "title": "The Diagnostic Challenge",
        "icon": "psychology",
        "type": "plain_text",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": "Diagnosis is more difficult in early symmetric disease where there may be no objective signs. EDTs (Electrodiagnostic tests) may be helpful in such cases (pp. 94–6). Typical ‘optic neuropathy’ features may be seen in other diseases (e.g. central scotoma, dcolour vision, or 2° optic atrophy in retinal disorders). The challenge is thus first to recognize the optic neuropathy and then to elucidate the cause."
      },
      {
        "title": "Red Flag: Unexplained Neuropathy",
        "icon": "report_problem",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Unexplained optic neuropathy requires urgent investigation (see E Atypical optic neuritis, p. 742).",
          "Rule out serious disease such as compression 2° to a tumour."
        ]
      },
      {
        "title": "Table 16.2 Clinical Features: Optic Nerve vs Macular Disease",
        "icon": "compare",
        "type": "table",
        "layout": "full_width",
        "color_theme": "purple",
        "content": {
          "headers": [
            "Feature",
            "Optic Neuropathy",
            "Macular Disease"
          ],
          "rows": [
            [
              "Hx: Main complaint",
              "Grey/ darkness",
              "Distortion"
            ],
            [
              "Hx: Scotoma",
              "Negative",
              "Positive"
            ],
            [
              "Hx: Associated symptoms",
              "May have retrobulbar pain, e.g. on eye movement",
              "May have micropsia, hyperopic shift"
            ],
            [
              "Exam: VA",
              "Variable d",
              "dd"
            ],
            [
              "Exam: Colour vision*",
              "d or dd",
              "Normal or mild d"
            ],
            [
              "Exam: RAPD",
              "+ to ++++",
              "− or (±)"
            ],
            [
              "Test: Perimetry",
              "Central, centrocaecal, arcuate, or altitudinal defects",
              "Central scotoma"
            ],
            [
              "Test: Amsler chart",
              "Scotoma",
              "Metamorphopsia"
            ],
            [
              "Test: VEP latency",
              "d",
              "Normal or mild d"
            ]
          ]
        }
      },
      {
        "title": "Important Note on Colour Vision",
        "icon": "palette",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "yellow",
        "content": "* Classically, optic neuropathies preferentially affect the red–green axis, and macular disease the blue–yellow axis, but there are many exceptions to this (e.g. glaucoma preferentially affects the blue–yellow axis)."
      },
      {
        "title": "Typical Optic Neuritis: Definitions",
        "icon": "menu_book",
        "type": "mindmap",
        "layout": "full_width",
        "color_theme": "green",
        "content": {
          "center": "Inflammation of the Optic Nerve",
          "branches": [
            "Papillitis (swollen disc)",
            "Retrobulbar neuritis (disc is spared)",
            "Neuroretinitis (retinal involvement, 'macular star')"
          ]
        }
      },
      {
        "title": "Acute Demyelinating Optic Neuritis",
        "icon": "biotech",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Commonest cause is demyelination.",
          "Incidence: 1–3/100,000/y.",
          "Occurs in up to 70% of patients with known MS.",
          "Presenting symptom of MS in 20%.",
          "Demographics: Majority female (♀:♂ 3:1), aged 20–50.",
          "Presentation: Usually unilateral, though bilateral occurs."
        ]
      },
      {
        "title": "Box 16.1 Features of Typical Optic Neuritis",
        "icon": "check_box",
        "type": "remember",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": {
          "mnemonic": "TYPICAL ON",
          "explanation": "Age 20-50; Unilateral; Worsens over hours/days; Recovery starts within 2wk; Retrobulbar pain (worse on eye movement); dcolour vision; RAPD. (Source: Beck RW et al, ONTT study, 1992)."
        }
      },
      {
        "title": "Clinical Features: Acute Stage",
        "icon": "medical_services",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Rapid dVA over hours/days (rarely become NPL).",
          "Recovery starts within 2wk and may continue for a few months.",
          "dcontrast sensitivity, dcolour vision, variable field loss.",
          "Retrobulbar pain: present in 90%; often worse on eye movement, may be very severe, usually precedes dVA.",
          "Photopsia.",
          "RAPD (may be absent if pre-existing contralateral disease).",
          "Disc swelling: Only one-third of cases.",
          "Disc Appearance: Should NOT be pale in acute stages of first episode; may have few haemorrhages, retinal exudates."
        ]
      },
      {
        "title": "Multiple Sclerosis (MS) Overview",
        "icon": "psychology",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "T-cell-mediated autoimmune neurodegenerative disorder.",
          "Inflammation in CNS myelin followed by hardening (sclerosis).",
          "Commoner in northern European ancestry.",
          "UK Incidence: 3 to 7/100,000/y.",
          "Diagnosis: Clinical history + exam consistent with demyelination. Supported by MRI/CSF analysis showing lesions disseminated in time (≥2 episodes) and space (≥2 separate locations)."
        ]
      },
      {
        "title": "Ophthalmic Features of MS",
        "icon": "remove_red_eye",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "green",
        "content": [
          "Optic neuritis.",
          "Internuclear ophthalmoplegia (INO).",
          "Isolated VF defects (lesions in any part of afferent visual system).",
          "Uveitis: Periphlebitis and intermediate uveitis are commonest.",
          "Nystagmus."
        ]
      },
      {
        "title": "Table 16.3 MS Subtypes (NICE CG186/QS108)",
        "icon": "category",
        "type": "table",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Subtype",
            "Incidence at Onset",
            "Description"
          ],
          "rows": [
            [
              "Relapsing–remitting MS (RRMS)",
              "85%",
              "Symptomatic neurological event (≥24h), followed by complete or almost complete resolution, with remission periods."
            ],
            [
              "2° progressive MS",
              "Two-thirds of RRMS develop this in 10y",
              "Gradually more symptomatic attacks, with fewer remission periods."
            ],
            [
              "1° progressive MS",
              "10–15%",
              "Symptoms occur without remission within 1y."
            ]
          ]
        }
      },
      {
        "title": "MS Management & Prognosis",
        "icon": "healing",
        "type": "plain_text",
        "layout": "half_width",
        "color_theme": "green",
        "content": "Treatment: Under care of MS specialist. Acute attacks: Glucocorticoids or plasmapheresis. Immunomodulatory therapies aim to d attacks, i remission, and d disability. Prognosis: Variable condition. Lesion load on MRI does not correlate well with relapse rate or disability score. Life expectancy: Normal or near normal."
      },
      {
        "title": "Use of OCT in MS",
        "icon": "biotech",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Monitoring Disease: Meta-analysis shows reduction in peripapillary retinal nerve fibre layer (pRNFL).",
          "With ON history: mean 20.4 microns reduction.",
          "Without ON history: mean 7.1 microns reduction compared to controls.",
          "Acute ON: GCL–inner plexiform layer thinning within weeks; pRNFL reduction (10–40 microns) within 3–6mo.",
          "Monitoring Treatment: Macular OCT recommended for fingolimod (sphingosine-1-phosphate receptor modulator).",
          "FAME (Fingolimod-Associated Macular oEdema): occurs in 0.3%, higher rate with prior uveitis, usually at 3–4mo."
        ]
      },
      {
        "title": "Neuromyelitis Optica Spectrum Disorders (NMOSD)",
        "icon": "lan",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "purple",
        "content": [
          "Idiopathic antibody-mediated inflammatory disease (formerly Devic’s disease).",
          "Predilection: Optic nerves and spinal cord; brain relatively spared.",
          "Demographics: Female preponderance; mean onset late 30y.",
          "Suspect if: Profound visual loss, simultaneous bilateral ON, sequential recurrent ON with normal MRI head, or LETM (contiguous ≥3 segment spinal cord MRI lesion)."
        ]
      },
      {
        "title": "NMOSD Diagnosis Criteria",
        "icon": "fact_check",
        "type": "plain_text",
        "layout": "half_width",
        "color_theme": "purple",
        "content": "Diagnosis requires exclusion of alternative causes and either: 1. AQP4-IgG positive + 1 core clinical characteristic OR 2. AQP4-IgG negative + 2 core clinical characteristics (at least one must be ON, acute myelitis with LETM, or area postrema syndrome)."
      },
      {
        "title": "NMOSD Core Clinical Characteristics",
        "icon": "list",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "purple",
        "content": [
          "Optic neuritis.",
          "Acute myelitis with Longitudinally Extensive Transverse Myelitis (LETM).",
          "Area Postrema Syndrome: lesions causing vomiting/hiccups."
        ]
      },
      {
        "title": "NMOSD Investigations",
        "icon": "science",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Serum AQP4-IgG: Positive in 75%, >99% specificity. Use cell-based assays.",
          "If AQP4-IgG negative: Test for myelin oligodendrocyte glycoprotein (MOG) antibodies.",
          "MRI head and spine (cervical/thoracic) with contrast.",
          "CSF Analysis: 30% show pleocytosis (>50 leucocytes/mL, usually monocytes/lymphocytes).",
          "Oligoclonal bands: transiently present (rare).",
          "CSF glial fibrillary acidic protein: elevated for days/weeks post-episode."
        ]
      },
      {
        "title": "NMOSD Treatment Protocols",
        "icon": "medication",
        "type": "process",
        "layout": "full_width",
        "color_theme": "green",
        "content": [
          "Step 1 (Acute): High-dose IVMP (1g 1x/d for 3–5d) + long oral taper.",
          "Step 2 (Non-responsive): Consider plasmapheresis for severe manifestations.",
          "Step 3 (Long-term Immunosuppression): Mycophenolate (d relapse by 87%; 36% failure rate).",
          "Step 4 (Alternative Immunosuppression): Azathioprine (d relapse by 70%; 53% failure rate).",
          "Step 5 (Biologics): Rituximab (d relapse by 88%; 33% failure rate).",
          "Step 6 (Emerging): C5a complement inhibitor (eculizumab) in phase III investigation."
        ]
      },
      {
        "title": "Warning: MS Treatment in NMOSD",
        "icon": "warning",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "NB: NMOSD is aggravated by the immunomodulatory treatments used in MS."
        ]
      },
      {
        "title": "NMOSD Prognosis Charts",
        "icon": "leaderboard",
        "type": "chart",
        "layout": "half_width",
        "color_theme": "red",
        "content": {
          "type": "bar",
          "data": [
            {
              "label": "Monophasic 5y Survival",
              "value": 90
            },
            {
              "label": "Relapsing 5y Survival",
              "value": 70
            },
            {
              "label": "Monophasic Perm. Visual Loss",
              "value": 20
            },
            {
              "label": "Relapsing Perm. Visual Loss (5y)",
              "value": 50
            }
          ]
        }
      },
      {
        "title": "NMOSD Prognosis: Additional Data",
        "icon": "analytics",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Untreated prognosis is poor.",
          "High cervical spine lesions can cause neurogenic respiratory failure.",
          "Relapsing NMOSD: 55% relapse within 1y; 90% within 5y.",
          "Monophasic: 30% have permanent paralysis in one/both legs."
        ]
      },
      {
        "title": "Anti-Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies",
        "icon": "biotech",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "MOG is exclusively on oligodendrocyte/myelin surfaces in CNS.",
          "Reported in: Paediatric MS, ADEM, and AQP4-seronegative NMOSD.",
          "Suspected as an associated marker, may not be pathogenic.",
          "Prognosis: Adults with NMOSD who are AQP4-IgG negative but MOG-positive tend to have fewer relapses and better overall prognosis."
        ]
      },
      {
        "title": "Atypical Optic Neuritis: Investigation",
        "icon": "search",
        "type": "process",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "MRI (gadolinium-enhanced)",
          "CXR, FBC, ESR, CRP, U+E, Glu, LFTs",
          "ACE, ANA, ANCA, Syphilis serology",
          "Genetic testing for LHON",
          "LP (CSF microscopy, protein, Glu, oligoclonal bands, cytology)"
        ]
      },
      {
        "title": "Table 16.4: Differential Diagnosis of Acute/Subacute Optic Neuropathy",
        "icon": "difference",
        "type": "table",
        "layout": "full_width",
        "color_theme": "purple",
        "content": {
          "headers": [
            "Diagnosis",
            "Key Clinical Features"
          ],
          "rows": [
            [
              "Optic neuritis (typical)",
              "Age 20–50, unilateral, dVA over hours/days, recovery in 2wk, retrobulbar pain."
            ],
            [
              "Compressive",
              "Progressive dVA, disc pallor ± pain, involvement of other local structures."
            ],
            [
              "Sphenoid sinus disease",
              "Persistent severe pain, pyrexia, history of sinusitis; consider fungal disease in immunocompromised/diabetic ketoacidosis/elderly. Can be silent/non-pyrexial."
            ],
            [
              "Sarcoidosis",
              "Progressive dVA ± uveitis, systemic signs, very steroid-sensitive."
            ],
            [
              "Vasculitis (e.g. SLE)",
              "Progressive dVA ± uveitis, symptoms/signs of vasculitis."
            ],
            [
              "Syphilis",
              "Progressive dVA, disc swelling ± uveitis; CSF leucocytosis; systemic signs; may be HIV +ve."
            ],
            [
              "AION",
              "Sudden painless dVA, altitudinal field loss, swollen disc (segmental), older age."
            ],
            [
              "Toxic or nutritional",
              "Slowly progressive symmetrical dVA with central scotomas; relevant history."
            ],
            [
              "LHON",
              "Severe sequential dVA over weeks/months, pupil spared, telangiectatic vessels (acute); young adult ♂; FH."
            ],
            [
              "Post-viral demyelination",
              "Often bilateral dVA post-viral/vaccination, children/young adults; ± ADEM/vitritis."
            ]
          ]
        }
      },
      {
        "title": "Typical Optic Neuritis: Treatment Controversy",
        "icon": "gavel",
        "type": "plain_text",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": "Treatment remains controversial. IVMP may hasten visual recovery but did not affect final VA in the ONTT study. No conclusive evidence that steroids (IV/PO) are beneficial for long-term recovery of VA, VF, or contrast sensitivity. May be offered to those with MS, poor vision in other eye, or severe pain."
      },
      {
        "title": "Typical Optic Neuritis: Prognosis Stats",
        "icon": "trending_up",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "green",
        "content": [
          "Visual Recovery: >90% attain 6/9 in affected eye.",
          "Persistent abnormalities: colour perception, contrast sensitivity, stereopsis, or field may persist even if VA > 6/6.",
          "Recurrence: 1/3 have further episode within 5y.",
          "Risk Factors for MS: ♀ sex, multiple MRI white matter lesions, CSF oligoclonal bands.",
          "15y MS Probability: 25% if normal MRI; 72% if >1 white matter lesion."
        ]
      },
      {
        "title": "Optic Neuritis in Children",
        "icon": "child_care",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Commonly bilateral.",
          "Disc swelling more often present than in adults.",
          "MS Risk Factors: White matter lesions on brain imaging, CSF oligoclonal bands, older age at presentation."
        ]
      }
    ]
  },
  "chapterId": "neuro",
  "seqId": 13,
  "_serverSynced": true
}